Fulcrum Therapeutics, Inc. (FULC)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
FULC Insider Trading Activity
FULC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,831 | 1 | 100 |
Related Transactions
| Tourangeau Greg | Principal Accounting Officer | 0 | $0 | 1 | $1,831 | $-1,831 |
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Fulcrum Therapeutics, Inc.
Over the last 12 months, insiders at Fulcrum Therapeutics, Inc. have bought $0 and sold $1,831 worth of Fulcrum Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fulcrum Therapeutics, Inc. have bought $13.54M and sold $1.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 43,360 shares for transaction amount of $492,028 was made by Sapir Alex (See Remarks) on 2024‑03‑04.
List of Insider Buy and Sell Transactions, Fulcrum Therapeutics, Inc.
| 2024-05-07 | Sale | Tourangeau Greg | Principal Accounting Officer | 236 0.0004% | $7.76 | $1,831 | -45.62% | |
| 2024-03-08 | Sale | Tourangeau Greg | Vice President, Finance | 4,884 0.0084% | $11.72 | $57,219 | -44.40% | |
| 2024-03-04 | Sapir Alex | See Remarks | 43,360 0.0707% | $11.35 | $492,028 | -44.92% | ||
| 2023-05-10 | Sale | Tourangeau Greg | Principal Accounting Officer | 210 0.0004% | $3.31 | $695 | +46.48% | |
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. | director | 1.92M 3.8009% | $13.00 | $25M | -68.65% | ||
| 2023-01-13 | Sale | Gould Robert J | Interim President & CEO | 6,766 0.0142% | $15.00 | $101,490 | -71.09% | |
| 2023-01-04 | RA CAPITAL MANAGEMENT, L.P. | director | 180,703 0.3049% | $7.28 | $1.31M | -52.17% | ||
| 2022-12-27 | RA CAPITAL MANAGEMENT, L.P. | director | 4,089 0.009% | $5.99 | $24,510 | -34.44% | ||
| 2022-12-19 | RA CAPITAL MANAGEMENT, L.P. | director | 98,787 0.2145% | $5.90 | $582,814 | -34.44% | ||
| 2022-12-16 | RA CAPITAL MANAGEMENT, L.P. | director | 1.34M 3.0203% | $5.42 | $7.27M | -25.98% | ||
| 2022-12-15 | RA CAPITAL MANAGEMENT, L.P. | director | 237,029 0.5283% | $5.50 | $1.3M | -27.74% | ||
| 2022-12-14 | RA CAPITAL MANAGEMENT, L.P. | director | 824,600 1.8392% | $5.46 | $4.5M | -27.21% | ||
| 2022-06-07 | Sale | Gould Robert J | 71,435 0.1753% | $8.09 | $577,895 | -23.70% | ||
| 2022-06-02 | Sale | Gould Robert J | 16,689 0.043% | $7.92 | $132,162 | -16.89% | ||
| 2022-04-07 | Sale | Gould Robert J | 5,631 0.0145% | $24.02 | $135,228 | -68.29% | ||
| 2022-04-01 | Sale | Gould Robert J | 52,552 0.1313% | $24.26 | $1.27M | -69.08% | ||
| 2021-08-11 | Sale | Stuart Bryan | See Remarks | 28,000 0.0899% | $23.75 | $665,000 | -25.57% | |
| 2021-08-10 | Sale | Stuart Bryan | See Remarks | 32,000 0.0815% | $17.50 | $560,000 | -19.71% | |
| 2021-08-10 | Sale | Moxham Christopher | Chief Scientific Officer | 51,785 0.1326% | $17.60 | $911,416 | -19.71% | |
| 2021-06-28 | GERAGHTY JAMES A | director | 10,000 0.0312% | $9.16 | $91,600 | +68.04% |
Insider Historical Profitability
| Tourangeau Greg | Principal Accounting Officer | 11571 0.0214% | $36,448.65 | 0 | 3 | |
| RA CAPITAL MANAGEMENT, L.P. | director | 11609704 21.5077% | $36.57M | 7 | 0 | |
| LEVIN MARK J | 5962202 11.0453% | $18.78M | 1 | 0 | +2.11% | |
| Third Rock Ventures III, L.P. | 10 percent owner | 5962202 11.0453% | $18.78M | 1 | 0 | +2.11% |
| Third Rock Ventures IV, L.P. | 10 percent owner | 2343154 4.3408% | $7.38M | 1 | 0 | +2.11% |
| Casdin Capital, LLC | 10 percent owner | 604285 1.1195% | $1.9M | 1 | 0 | +2.11% |
| 6 Dimensions Capital, L.P. | 10 percent owner | 559821 1.0371% | $1.76M | 1 | 0 | +2.11% |
| Sanofi | 10 percent owner | 558035 1.0338% | $1.76M | 1 | 0 | +2.11% |
| Gould Robert J | Interim President & CEO | 499864 0.926% | $1.57M | 0 | 21 | |
| Wallace Owen B. | Chief Scientific Officer | 127088 0.2354% | $400,327.20 | 0 | 6 | |
| GERAGHTY JAMES A | director | 90714 0.1681% | $285,749.10 | 1 | 0 | +68.04% |
| Cadavid Diego | SVP Clinical Development | 65714 0.1217% | $206,999.10 | 0 | 12 | |
| Sapir Alex | See Remarks | 43360 0.0803% | $136,584.00 | 1 | 0 | <0.0001% |
| Thomson Peter G. | VP Finance & Accounting | 2300 0.0043% | $7,245.00 | 1 | 5 | +68.04% |
| Oltmans Curtis Gale | SVP, General Counsel | 1088 0.002% | $3,427.20 | 1 | 0 | +68.04% |
| Morabito Christopher | Chief Medical Officer | 1100 0.002% | $3,465.00 | 1 | 0 | +68.04% |
| Stuart Bryan | See Remarks | 0 0% | $0 | 0 | 2 | |
| Moxham Christopher | Chief Scientific Officer | 0 0% | $0 | 0 | 1 |
Historical Insider Profitability vs. Competitors
$2,951,087 | 73 | -5.15% | $146.04M | |
$613,304,943 | 46 | 11.85% | $172.61M | |
$35,190,048 | 32 | 37.32% | $172.93M | |
$63,049,419 | 31 | 2.87% | $183.04M | |
$79,019,806 | 27 | 7.24% | $162.07M | |
$6,915,275 | 21 | -32.61% | $169.13M | |
$2,484,989 | 17 | -17.86% | $176.55M | |
$4,701,608 | 14 | -4.34% | $183.35M | |
$91,870,774 | 13 | 3.64% | $150.12M | |
$2,788,839 | 12 | 6.73% | $159.32M | |
Fulcrum Therapeutics, Inc. (FULC) | $19,659,196 | 11 | 21.81% | $170.03M |
$17,675,244 | 7 | 92.20% | $174.13M | |
$8,286,963 | 6 | 3.09% | $182.94M | |
$88,549,962 | 5 | -16.91% | $181.51M | |
$556,839 | 5 | 13.42% | $150.5M | |
$63,981 | 5 | -11.55% | $164.39M | |
$47,368,750 | 2 | -21.95% | $166.89M | |
$300,016 | 1 | -50.33% | $170.79M | |
$879,499 | 1 | 28.50% | $157.7M |
FULC Institutional Investors: Active Positions
| Increased Positions | 58 | +34.73% | 8M | +13.48% |
| Decreased Positions | 73 | -43.71% | 14M | -23.61% |
| New Positions | 26 | New | 2M | New |
| Sold Out Positions | 34 | Sold Out | 8M | Sold Out |
| Total Postitions | 152 | -8.98% | 52M | -10.13% |
FULC Ownership Change vs Market
Institutional Investor Ownership
| Ra Capital Management, L.P. | $31,915.00 | 18.94% | 10.23M | 0 | 0% | 2024-12-31 |
| Tcg Crossover Management, Llc | $16,380.00 | 9.72% | 5.25M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $16,129.00 | 9.57% | 5.17M | -537,098 | -9.41% | 2024-12-31 |
| Nantahala Capital Management, Llc | $14,913.00 | 8.85% | 4.78M | +1,796 | +0.04% | 2024-12-31 |
| Suvretta Capital Management, Llc | $10,416.00 | 6.18% | 3.34M | +2M | +182.25% | 2024-12-31 |
| Vanguard Group Inc | $10,139.00 | 6.02% | 3.25M | -24,985 | -0.76% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $9,360.00 | 5.56% | 3M | +1M | +50% | 2024-12-31 |
| Morgan Stanley | $4,779.00 | 2.84% | 1.53M | +1M | +336.78% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $4,426.00 | 2.63% | 1.42M | -4,805 | -0.34% | 2024-12-31 |
| Woodline Partners Lp | $4,401.00 | 2.61% | 1.41M | +739,713 | +110.27% | 2024-12-31 |